SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland.

Autor:	Yeung A; Glasgow Caledonian University, Glasgow, UK alan.yeung@phs.scot.; Public Health Scotland, Edinburgh, UK., Wilkinson M; Glasgow Caledonian University, Glasgow, UK.; Public Health Scotland, Edinburgh, UK., Bishop J; Public Health Scotland, Edinburgh, UK., Taylor B; Public Health Scotland, Edinburgh, UK., Palmateer N; Glasgow Caledonian University, Glasgow, UK.; Public Health Scotland, Edinburgh, UK., Barnsdale L; Public Health Scotland, Edinburgh, UK., Lang J; Public Health Scotland, Edinburgh, UK., Cameron C; Public Health Scotland, Edinburgh, UK., McCormick D; Public Health Scotland, Edinburgh, UK., Clusker T; Public Health Scotland, Edinburgh, UK., McAuley A; Glasgow Caledonian University, Glasgow, UK.; Public Health Scotland, Edinburgh, UK., Hutchinson S; Glasgow Caledonian University, Glasgow, UK.; Public Health Scotland, Edinburgh, UK.
Jazyk:	angličtina
Zdroj:	Journal of epidemiology and community health [J Epidemiol Community Health] 2024 May 09; Vol. 78 (6), pp. 380-387. Date of Electronic Publication: 2024 May 09.
DOI:	10.1136/jech-2023-221602
Abstrakt:	Background: There is limited evidence quantifying the risk of severe COVID-19 disease among people with opioid dependence. We examined vaccine uptake and severe disease (admission to critical care or death with COVID-19) among individuals prescribed opioid agonist therapy (OAT). Method: A case-control design was used to examine vaccine uptake in those prescribed OAT compared with the general population, and the association between severe disease and OAT. In both analyses, 10 controls from the general population were matched (to each OAT recipient and COVID-19 case, respectively) according to socio-demographic factors. Conditional logistic regression was used to estimate rate ratios (RR) for severe disease. Results: Vaccine uptake was markedly lower in the OAT cohort (dose 1: 67%, dose 2: 53% and dose 3: 31%) compared with matched controls (76%, 72% and 57%, respectively). Those prescribed OAT within the last 5 years, compared with those not prescribed, had increased risk of severe COVID-19 (RR 3.38, 95% CI 2.75 to 4.15), particularly in the fourth wave (RR 6.58, 95% CI 4.20 to 10.32); adjustment for comorbidity and vaccine status attenuated this risk (adjusted RR (aRR) 2.43, 95% CI 1.95 to 3.02; wave 4 aRR 3.78, 95% CI 2.30 to 6.20). Increased risk was also observed for those prescribed OAT previously (>3 months ago) compared with recently (aRR 1.74, 95% CI 1.11 to 2.71). Conclusions: The widening gap in vaccine coverage for those prescribed OAT, compared with the general population, is likely to have exacerbated the risk of severe COVID-19 in this population over the pandemic. However, continued OAT use may have provided protection from severe COVID-19 among those with opioid dependence. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu